Neuropeptide systems (CRF, NPY, substance P, galanin, vasopressin, nociceptin) offer novel therapeutic targets for depression and anxiety with potentially better efficacy and fewer side effects than current monoamine-based drugs.
6 new targetsCRF, NPY, substance P, galanin, vasopressin, and nociceptin each offer mechanistically distinct approaches to depression and anxiety beyond monoamines
What the researchers found
Multiple neuropeptide systems (CRF, NPY, substance P/NK1, galanin, vasopressin, nociceptin) offer novel antidepressant and anxiolytic targets with mechanisms fundamentally different from monoamine-based drugs.
Why it matters
Depression and anxiety affect hundreds of millions worldwide, and current drugs work for only ~60% of patients. Neuropeptide-targeted drugs could help the treatment-resistant remainder.
How the study worked
Comprehensive review of neuropeptide targets for depression and anxiety, covering CRF receptors, NPY, substance P/NK1, galanin, vasopressin V1b, and nociceptin/NOP, with preclinical and clinical evidence.
What this study cannot tell us
Review from 2003. Several neuropeptide drug candidates have since had mixed clinical results (notably NK1 antagonists). Translation from animal models to human efficacy remains challenging.
How to read the evidence
Strong evidence from a comprehensive review mapping the full landscape of neuropeptide targets with preclinical and early clinical data.
When this study was published
Published in 2003. Some targets (NK1 antagonists) had disappointing clinical results, while others (CRF, NPY) remain active areas of development.
The bigger picture
Psychiatry is evolving from monoamine-centric to neuropeptide-inclusive pharmacology. Each peptide target addresses a different aspect of mood/anxiety disorders, enabling more precise treatment matching.
Questions still open
- Why have some neuropeptide drugs failed in clinical trials despite preclinical promise?
- Could neuropeptide combination therapy address treatment-resistant depression?
- Which neuropeptide target is most promising for near-term clinical success?
Common questions
Why do we need new depression/anxiety drugs?
Which neuropeptide target is most promising?
Read the original research
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
Trends in pharmacological sciences, 24(11), 580-8
Citation
Holmes, Andrew; Heilig, Markus; Rupniak, Nadia M J; Steckler, Thomas; Griebel, Guy. (2003). Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.. Trends in pharmacological sciences, 24(11), 580-8.